A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms

Trial Profile

A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs MDG 1011 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors MediGene AG
  • Most Recent Events

    • 09 May 2018 According to a MediGene AG media release, company intends to present preliminary data on certain aspects of the trial at scientific conferences and final data will be available towards the end of 2019.
    • 09 May 2018 According to a MediGene AG media release, company expects to conduct the first trial cohorts of Phase I in the course of 2018.
    • 09 May 2018 According to a MediGene AG media release, data on the successful production of acute myeloid leukemia (AML) dendritic cell (DC) vaccines from this trial were presented at the AACR annual conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top